TEVA INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Teva Pharmaceutical Industries Limited

NEW YORK--()--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Teva Pharmaceutical Industries Limited (“Teva”) (NYSE:TEVA) violated federal securities laws.

Click here to learn about the case: http://docs.wongesq.com/TEVA-Request-Form-1686. There is no cost or obligation to you.

On August 2, 2016, Teva completed its acquisition of Allergan plc’s generics business, Actavis Generis. Teva continued to make positive statements concerning the integration of the business, growth on intangible assets and goodwill, and general benefits of the acquisition. Then on August 3, 2017, Teva lowered its outlook and recorded a $6.1 billion impairment charge.

To learn more about the investigation of Teva contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/TEVA-Request-Form-1686.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

The Law Offices of Vincent Wong
Vincent Wong, Esq., 212-425-1140
Fax: 866-699-3880
vw@wongesq.com

Release Summary

The Law Offices of Vincent Wong reminds investors of an investigation concerning Teva Pharmaceutical Industries Limited

Contacts

The Law Offices of Vincent Wong
Vincent Wong, Esq., 212-425-1140
Fax: 866-699-3880
vw@wongesq.com